Диссертация (1154797), страница 18
Текст из файла (страница 18)
Rakugi H., Enya K., Sugiura K. et al. Comparison of the efficacy and safety ofazilsartan with that of candesartan cilexetil in Japanese patients with grade I-IIessential hypertension: a randomized, double-blind clinical study // Hypertens.Res. 2012; 35:552-8.127. Ronco C., McCullough P., Anker S. et al. Cardio-renal syndromes: report fromthe consensus conference of the Acute Dialysis Quality Initiative.
Eur Heart J2010;31:703–11.128. Roush G.C., Halford T.R., Guddati A.K. Chlortalidone compared withhydrochlorothiazide in reducing cardiovascular events: systematic review andnetwork meta-analyses // Hypertension. 2012;59:1110-17129. Ruggenenti P., Remuzzi G.
Dealing with renin-angiotensin inhibitors, don’tmind serum creatinine. Am J Nephrol 2012;36:427–29128130. Sever P.S., Messerli F.H. Hypertension management 2011: optimalcombination therapy // Eur. Heart J. 2011;32(20):2499–2506.131. SHEP Cooperative Research Group. Prevention of stroke by antihypertensivedrug treatment in older persons with isolated systolic hypertension.
Final resultsof the Systolic Hypertension in the Elderly Program (SHEP). JAMA.1991;265:3255–64132. Shuster J.E., Bleske B.E., Dorsch M.P. Clinical utility of azilsartanchlorthalidone fixed combination in the management of hypertension. VascHealth Risk Manag 2012;8:381–7133.
Sica D., Bakris G.L., White W.B. et al. Blood pressure lowering efficacy of thefixed dose combination of azilsartan and chlorthalidone: a factorial study // J.Clin. Hypertens (Greenwich). 2012;14:284-92134. Sica D., White W.B., Weber M.A. et al. Comparison of the novel angiotensinII receptor blocker azilsartan medoxomil vs valsartan by ambulatory bloodpressure monitoring // J.
Clin. Hypertens (Greenwich). 2011; 13: 467-72.135. Smink P.A., Lambers Heerspink H.J., Gansevoort R.T. et al. Albuminuria,estimated GFR, traditional risk factors, and incident cardiovascular disease: thePREVEND (Prevention of Renal and Vascular Endstage Disease) study. Am JKidney Dis. 2012;60(5):804-11136. SPRINT Research Group; Wright J.T. Jr., Williamson J.D., Whelton P.K. et al.A randomized trial of intensive versus standard blood-pressure control // N. Engl.J. Med.
2015;373(22):2103–2116137. Stacy S.R., Suarez-Cuervo C., Berger Z. et al. Role of troponin in patients withchronic kidney disease and suspected acute coronary syndrome: a systematicreview. Ann Intern Med 2014;161:502–12.138. Stanifern J., Muiru A., Tazeen H. et al. Pate chronic kidney disease in low- andmiddle-income countries. Nephrol Dial Transplant.
2016;31:868–74.139. Thompson S., James M., Wiebe N. et al. Cause of death in patients withreduced kidney function. J Am Soc Nephrol 2015;26:2504–11.129140. Vejakama .P, Ingsathit A., Attia J. et al. Epidemiological study of chronickidney disease progression: a large-scale population-based cohort study.Medicine. 2015;94(4):e475141. Verdecchia P., Reboldi G.P. Hypertension and microalbuminuria: the newdetrimental duo. Blood Press. 2004;13(4):198-211142. Weber M.A., Schiffrin E.L., White W.B. et al.
Clinical practice guidelines forthe management of hypertension in the community: a statement by the AmericanSociety of Hypertension and the International Society of Hypertension. J ClinHypertens 2014;16:14-26143. WebsterA.C., NaglerE.V., MortonR.L.ChronicKidneyDisease.Lancet. 2017; 389:1238-1252.144. White W.B., Weber M.A., Sica D. et al. Effects of the angiotensin receptorblocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory andclinic blood pressure in patients with stages 1 and 2 hypertension // Hypertension.2011; 57: 413-20.145. Zaiken K, Cheng JW. Azilsartan medoxomil: a new angiotensin receptorblocker.
Clin Ther 2011;33:1577-89.146. Zhang L., Fang W. et al. Prevalence of chronic kidney disease in China: across-sectional survey. Lancet 2012; 379: 815–822147. Zhang L., Zhang P., Wang .F et al. Prevalence and factors associated withCKD: a population study from Beijing. Am J Kidney Dis 2008; 51: 373–384.148. Zhang Q.L., Rothenbacher D. Prevalence of chronic kidney disease inpopulation-based studies: systematic review.
BMC Public Health 2008; 8: 117124.149. Zhu P., Liu Y., Han L. et al. Serum uric acid is associated with incident chronickidney disease in middle-aged populations: a meta-analysis of 15 cohort studies.PLoS One. 2014;9(6):e100801150. Zoccali C., Kramer A., Jager K.J. Epidemiology of CKD in Europe: anuncertain scenario. Nephrol Dial Transplant 2010;25:1731–1733.130151. Zoccali C., Tripepi R., Torino C. et al. Ambulatory blood pressure monitoringand home blood pressure for the prognosis, diagnosis and treatment ofhypertension in dialysis patients. Nephrol Dial Transplant. 2015;30:1443–1448.152. Zyga S., Kolovos P.
Cardiovascular Disease and Chronic Inflammation in EndStage Kidney Disease. International Journal of Caring Sciences. 2013;6:29-36.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
